

6. Riser WH, Brodey RS, Biery DN. Bone infarctions associated with malignant bone tumors in dogs. *J Am Vet Med Assoc* 1972;160:414-421.
7. Newman ME, Johnson KA. Suspected intramedullary bone infarct subsequent to tibial plateau levelling osteotomy in a dog. *Aust Vet J* 2015;93:255-258.
8. Haney DR, Peck JN. Influence of canal preparation depth on the incidence of femoral medullary infarction with Zurich Cementless Canine Total Hip arthroplasty. *Vet Surg* 2009;38:673-676.
9. Marsolais GS, Peck JN, Berry C, et al. Femoral medullary infarction prevalence with the Zurich Cementless Canine Total Hip arthroplasty. *Vet Surg* 2009;38:677-680.
10. Sebestyen P, Marcellin-Little DJ, DeYoung BA. Femoral medullary infarction secondary to canine total hip arthroplasty. *Vet Surg* 2000;29:227-236.
11. Fenger CK, Bertone JJ, Biller D, et al. Generalized medullary infarction of the long bones in a horse. *J Am Vet Med Assoc* 1993;202:621-623.
12. Martig S, Lippold BS, Oevermann A, et al. Polyostotic bone lesions consistent with bone infarction in a horse. *Vet Rec* 2008;162:352-353.
13. Sánchez J, Gonzalo-Orden JM, Ginja MMD, et al. Imaging diagnosis—medullary tibial infarction in a horse. *Vet Radiol Ultrasound* 2010;51:159-161.
14. Thrall DE. *Textbook of veterinary diagnostic radiology*. 6th ed. St Louis: Elsevier, 2013.
15. Rana RS, Wu JS, Eisenberg RL. Periosteal reaction. *AJR Am J Roentgenol* 2009;193:W259-W272.
16. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). *J Am Vet Med Assoc* 1992;200:995-999.
17. Anfinsen KP, Grotmol T, Bruland OS, et al. Breed-specific incidence rates of canine primary bone tumors—a population based survey of dogs in Norway. *Can J Vet Res* 2011;75:209-215.
18. Withrow SJ, Vail DM, Page RL. *Withrow and MacEwen's small animal clinical oncology*. 5th ed. St Louis: Elsevier, 2013.
19. Misdorp W, Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma. *J Natl Cancer Inst* 1979;62:537-545.
20. Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. *Vet J* 1998;156:31-39.
21. Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996-2005). *J Am Vet Med Assoc* 2007;231:1076-1080.
22. Baumgärtner W, Boyce RW, Alldinger S, et al. Metaphyseal bone lesions in young dogs with systemic canine distemper virus infection. *Vet Microbiol* 1995;44:201-209.
23. Bahk WJ, Lee AH, Kang YK, et al. Infarct associated sarcoma: a possible pathogenesis based on histological observation of repair tissue origin in two cases. *Acta Oncol* 2010;49:868-872.
24. Mirra JM. Secondary malignant fibrous histiocytoma (arising in bone infarcts). In: Mirra JM, Picci P, Gold RH, eds. *Bone tumors: clinical, radiologic, and pathologic correlations*. Philadelphia: Lea & Febiger, 1989.



Correction: Effects of milbemyacin oxime, combined with spinosad, when administered orally to microfilaremic dogs infected with adult heartworms (*Dirofilaria immitis*)

In the article “Effects of milbemyacin oxime, combined with spinosad, when administered orally to microfilaremic dogs infected with adult heartworms (*Dirofilaria immitis*)” (*J Am Vet Med Assoc* 2018;252:1084-1089), the units reported in the “Adult heartworm counts” section of the results were incorrect. This section should read as follows:

Adult heartworm counts

Mean \pm SD adult heartworm counts were 26.4 ± 8.2 adult worms (range, 14 to 37 adult worms) in the control group, 24.1 ± 6.9 adult worms (range, 13 to 34 adult worms) in the 1X group, 25.9 ± 9.1 adult worms (range, 16 to 41 adult worms) in the 3X group, and 25.5 ± 6.5 adult worms (range, 7 to 35 adult worms) in the 5X group. There was no evidence of an effect of treatment group on adult heartworm counts ($P = 0.94$). In addition, contrasts comparing counts for each treated group to counts for the control group revealed no differences ($P \geq 0.55$).